Gene: Mybl2 (MYB proto-oncogene like 2) Rattus norvegicus
Analyze
Symbol:
Mybl2
Name:
MYB proto-oncogene like 2
RGD ID:
1308474
Description:
Predicted to have DNA-binding transcription activator activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Involved in positive regulation of neuron apoptotic process. Predicted to localize to Myb complex and nucleoplasm. Orthologous to human MYBL2 (MYB proto-oncogene like 2); INTERACTS WITH 1-naphthyl isothiocyanate; 2,3,7,8-tetrachlorodibenzodioxine; 6-propyl-2-thiouracil.
Type:
protein-coding
RefSeq Status:
PROVISIONAL
Also known as:
LOC296344; myb-related protein B; myeloblastosis oncogene-like 2
Orthologs:
Species
Gene symbol and name
Data Source
Assertion derived from
less info ...
Orthologs 1
Homo sapiens (human):
MYBL2 (MYB proto-oncogene like 2) HGNC
EggNOG, Ensembl, HomoloGene, Inparanoid, NCBI, OMA, OrthoDB, OrthoMCL, Panther, PhylomeDB, Treefam
Mus musculus (house mouse):
Mybl2 (myeloblastosis oncogene-like 2) HGNC
Treefam, EggNOG, OrthoMCL, NCBI, OMA, HomoloGene, Inparanoid, Panther, PhylomeDB, OrthoDB, Ensembl
Chinchilla lanigera (long-tailed chinchilla):
Mybl2 (MYB proto-oncogene like 2) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Pan paniscus (bonobo/pygmy chimpanzee):
MYBL2 (MYB proto-oncogene like 2) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Canis lupus familiaris (dog):
MYBL2 (MYB proto-oncogene like 2) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Ictidomys tridecemlineatus (thirteen-lined ground squirrel):
Mybl2 (MYB proto-oncogene like 2) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Sus scrofa (pig):
MYBL2 (MYB proto-oncogene like 2) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Chlorocebus sabaeus (African green monkey):
MYBL2 (MYB proto-oncogene like 2) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Heterocephalus glaber (naked mole-rat):
Mybl2 (MYB proto-oncogene like 2) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Other homologs 2
Homo sapiens (human):
MYBL1 (MYB proto-oncogene like 1) HGNC
OrthoDB
Alliance orthologs 3
Homo sapiens (human):
MYBL2 (MYB proto-oncogene like 2)
Alliance
DIOPT (Ensembl Compara|HGNC|Hieranoid|InParanoid|OMA|OrthoFinder|OrthoInspector|PANTHER|PhylomeDB|TreeFam)
Mus musculus (house mouse):
Mybl2 (myeloblastosis oncogene-like 2)
Alliance
DIOPT (Ensembl Compara|Hieranoid|InParanoid|OMA|OrthoFinder|OrthoInspector|PANTHER|PhylomeDB|TreeFam)
Saccharomyces cerevisiae (baker's yeast):
BAS1
Alliance
DIOPT (Ensembl Compara|OrthoInspector|PANTHER)
Drosophila melanogaster (fruit fly):
Myb
Alliance
DIOPT (InParanoid|OrthoFinder|OrthoInspector|PANTHER|PhylomeDB|TreeFam)
Latest Assembly:
Rnor_6.0 - RGSC Genome Assembly v6.0
Position:
Rat Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl Rnor_6.0 3 159,421,638 - 159,450,087 (+) NCBI Rnor6.0 Rnor_6.0 rn6 Rnor6.0 Rnor_6.0 Ensembl 3 159,421,671 - 159,450,086 (+) Ensembl Rnor6.0 rn6 Rnor6.0 Rnor_5.0 3 165,617,173 - 165,645,610 (+) NCBI Rnor5.0 Rnor_5.0 rn5 Rnor5.0 RGSC_v3.4 3 153,925,908 - 153,954,323 (+) NCBI RGSC3.4 rn4 RGSC3.4 RGSC_v3.1 3 153,831,924 - 153,858,958 (+) NCBI Celera 3 150,362,664 - 150,391,069 (+) NCBI Celera Cytogenetic Map 3 q42 NCBI
JBrowse:
View Region in Genome Browser (JBrowse)
Model
Imported Annotations - ClinVar
visual epilepsy ISO RGD:1318263 8554872 ClinVar Annotator: match by term: Focal seizures ClinVar PMID:32581362
Imported Annotations - CTD
hepatocellular carcinoma ISO RGD:1318263 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:28284560 Imported Annotations - MGI
acute myeloid leukemia ISS RGD:1318264 13592920 OMIM:601626 MouseDO myelodysplastic syndrome ISS RGD:1318264 13592920 OMIM:614286 MouseDO
(S)-nicotine decreases expression ISO RGD:1318263 6480464 Nicotine results in decreased expression of MYBL2 mRNA CTD PMID:16949557 1,2-dimethylhydrazine multiple interactions ISO RGD:1318264 6480464 Folic Acid inhibits the reaction [1, 2-Dimethylhydrazine results in increased expression of MYBL2 mRNA] CTD PMID:22206623 1,2-dimethylhydrazine increases expression ISO RGD:1318264 6480464 1, 2-Dimethylhydrazine results in increased expression of MYBL2 mRNA CTD PMID:22206623 1-naphthyl isothiocyanate increases expression EXP 6480464 1-Naphthylisothiocyanate results in increased expression of MYBL2 mRNA CTD PMID:30723492 14-Deoxy-11,12-didehydroandrographolide decreases expression ISO RGD:1318263 6480464 14-deoxy-11, 12-didehydroandrographolide results in decreased expression of MYBL2 mRNA CTD PMID:22101062 17alpha-ethynylestradiol multiple interactions ISO RGD:1318264 6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of MYBL2 mRNA CTD PMID:17942748 17alpha-ethynylestradiol increases expression ISO RGD:1318264 6480464 Ethinyl Estradiol results in increased expression of MYBL2 mRNA CTD PMID:17555576 , PMID:17942748 17beta-estradiol increases expression ISO RGD:1318263 6480464 Estradiol results in increased expression of MYBL2 mRNA CTD PMID:16474171 more ... 17beta-estradiol decreases expression ISO RGD:1318263 6480464 Estradiol results in decreased expression of MYBL2 mRNA CTD PMID:23373633 17beta-estradiol multiple interactions ISO RGD:1318264 6480464 ESR1 protein promotes the reaction [Estradiol results in increased expression of MYBL2 mRNA] CTD PMID:25210133 17beta-estradiol increases expression ISO RGD:1318264 6480464 Estradiol results in increased expression of MYBL2 mRNA CTD PMID:25210133 17beta-hydroxy-5alpha-androstan-3-one increases expression ISO RGD:1318263 6480464 Dihydrotestosterone results in increased expression of MYBL2 mRNA CTD PMID:17254854 2,2',4,4',5,5'-hexachlorobiphenyl multiple interactions ISO RGD:1318264 6480464 [2 more ... CTD PMID:25510870 2,2',5,5'-tetrachlorobiphenyl multiple interactions ISO RGD:1318264 6480464 [2 more ... CTD PMID:25510870 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1318264 6480464 [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of MYBL2 mRNA CTD PMID:17942748 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of MYBL2 mRNA CTD PMID:32109520 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1318264 6480464 Tetrachlorodibenzodioxin results in increased expression of MYBL2 mRNA CTD PMID:21496263 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1318263 6480464 Tetrachlorodibenzodioxin results in increased expression of MYBL2 mRNA CTD PMID:21496263 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1318264 6480464 Tetrachlorodibenzodioxin affects the expression of MYBL2 mRNA CTD PMID:21570461 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1318264 6480464 Tetrachlorodibenzodioxin results in decreased expression of MYBL2 mRNA CTD PMID:16611356 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:1318263 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of MYBL2 mRNA CTD PMID:28628672 4-hydroxynon-2-enal decreases expression ISO RGD:1318263 6480464 4-hydroxy-2-nonenal results in decreased expression of MYBL2 mRNA CTD PMID:12419474 5-fluorouracil increases expression ISO RGD:1318263 6480464 Fluorouracil results in increased expression of MYBL2 mRNA CTD PMID:16557594 5-fluorouracil affects response to substance ISO RGD:1318263 6480464 MYBL2 protein affects the susceptibility to Fluorouracil CTD PMID:15548681 6-propyl-2-thiouracil increases expression EXP 6480464 Propylthiouracil results in increased expression of MYBL2 mRNA CTD PMID:24780913 acetamide increases expression EXP 6480464 acetamide results in increased expression of MYBL2 mRNA CTD PMID:31881176 acrylamide increases expression EXP 6480464 Acrylamide results in increased expression of MYBL2 mRNA CTD PMID:28959563 aflatoxin B1 increases expression ISO RGD:1318263 6480464 Aflatoxin B1 results in increased expression of MYBL2 mRNA CTD PMID:22100608 aflatoxin B1 multiple interactions EXP 6480464 [sulforafan co-treated with Aflatoxin B1] affects the expression of MYBL2 mRNA CTD PMID:25450479 aflatoxin B1 increases expression EXP 6480464 Aflatoxin B1 results in increased expression of MYBL2 mRNA CTD PMID:22484513 more ... all-trans-retinoic acid decreases expression ISO RGD:1318263 6480464 Tretinoin results in decreased expression of MYBL2 mRNA CTD PMID:12875902 , PMID:17318229 all-trans-retinoic acid decreases expression ISO RGD:1318264 6480464 Tretinoin results in decreased expression of MYBL2 mRNA CTD PMID:16604517 benzo[a]pyrene increases mutagenesis ISO RGD:1318263 6480464 Benzo(a)pyrene results in increased mutagenesis of MYBL2 gene CTD PMID:25435355 benzo[a]pyrene increases expression ISO RGD:1318263 6480464 Benzo(a)pyrene results in increased expression of MYBL2 mRNA CTD PMID:32234424 benzo[a]pyrene decreases expression ISO RGD:1318264 6480464 Benzo(a)pyrene results in decreased expression of MYBL2 mRNA CTD PMID:17942131 benzo[a]pyrene decreases expression ISO RGD:1318263 6480464 Benzo(a)pyrene results in decreased expression of MYBL2 mRNA CTD PMID:20064835 bisphenol A increases expression ISO RGD:1318263 6480464 bisphenol A results in increased expression of MYBL2 mRNA CTD PMID:16474171 bisphenol A affects expression ISO RGD:1318263 6480464 bisphenol A affects the expression of MYBL2 mRNA CTD PMID:30903817 bisphenol A affects methylation ISO RGD:1318264 6480464 bisphenol A affects the methylation of MYBL2 promoter CTD PMID:27334623 bisphenol A decreases expression ISO RGD:1318263 6480464 bisphenol A results in decreased expression of MYBL2 mRNA CTD PMID:27685785 , PMID:29275510 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of MYBL2 mRNA CTD PMID:25181051 bisphenol F multiple interactions ISO RGD:1318263 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of MYBL2 mRNA CTD PMID:28628672 calcitriol decreases expression ISO RGD:1318263 6480464 Calcitriol results in decreased expression of MYBL2 mRNA CTD PMID:12875902 , PMID:21592394 calcitriol multiple interactions ISO RGD:1318263 6480464 [Testosterone co-treated with Calcitriol] results in decreased expression of MYBL2 mRNA CTD PMID:21592394 calyculin a decreases expression ISO RGD:1318264 6480464 calyculin A results in decreased expression of MYBL2 mRNA CTD PMID:25270620 carbon nanotube increases expression ISO RGD:1318264 6480464 Nanotubes, Carbon analog results in increased expression of MYBL2 mRNA, Nanotubes, Carbon results in increased expression of MYBL2 mRNA CTD PMID:25554681 carmustine increases expression EXP 6480464 Carmustine results in increased expression of MYBL2 mRNA CTD PMID:16005536 chlorpromazine decreases expression ISO RGD:1318263 6480464 Chlorpromazine analog results in decreased expression of MYBL2 mRNA CTD PMID:15924885 cisplatin increases expression ISO RGD:1318263 6480464 Cisplatin results in increased expression of MYBL2 mRNA CTD PMID:27594783 cisplatin decreases expression ISO RGD:1318263 6480464 Cisplatin results in decreased expression of MYBL2 mRNA CTD PMID:27392435 cobalt dichloride decreases expression ISO RGD:1318263 6480464 cobaltous chloride results in decreased expression of MYBL2 mRNA CTD PMID:19320972 cobalt dichloride increases expression EXP 6480464 cobaltous chloride results in increased expression of MYBL2 mRNA CTD PMID:24386269 copper atom increases expression EXP 6480464 Copper deficiency results in increased expression of MYBL2 mRNA CTD PMID:26033743 copper(0) increases expression EXP 6480464 Copper deficiency results in increased expression of MYBL2 mRNA CTD PMID:26033743 coumestrol multiple interactions ISO RGD:1318263 6480464 [Coumestrol co-treated with 2 more ... CTD PMID:19167446 coumestrol increases expression ISO RGD:1318263 6480464 Coumestrol results in increased expression of MYBL2 mRNA CTD PMID:19167446 cyclosporin A decreases expression ISO RGD:1318264 6480464 Cyclosporine results in decreased expression of MYBL2 mRNA CTD PMID:17942131 cyclosporin A decreases expression ISO RGD:1318263 6480464 Cyclosporine results in decreased expression of MYBL2 mRNA CTD PMID:19159671 more ... dexamethasone multiple interactions ISO RGD:1318263 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of MYBL2 mRNA CTD PMID:28628672 dibutyl phthalate decreases expression ISO RGD:1318264 6480464 Dibutyl Phthalate results in decreased expression of MYBL2 mRNA CTD PMID:21266533 dibutyl phthalate decreases expression EXP 6480464 Dibutyl Phthalate results in decreased expression of MYBL2 mRNA CTD PMID:21266533 dicrotophos increases expression ISO RGD:1318263 6480464 dicrotophos results in increased expression of MYBL2 mRNA CTD PMID:28302478 diethyl maleate increases expression EXP 6480464 diethyl maleate results in increased expression of MYBL2 mRNA CTD PMID:21161181 dioxygen decreases expression ISO RGD:1318263 6480464 Oxygen deficiency results in decreased expression of MYBL2 mRNA CTD PMID:26516004 doxorubicin decreases expression ISO RGD:1318263 6480464 Doxorubicin results in decreased expression of MYBL2 mRNA CTD PMID:30031762 Enterolactone multiple interactions ISO RGD:1318263 6480464 [Coumestrol co-treated with 2, 3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MYBL2 mRNA CTD PMID:19167446 exemestane increases expression ISO RGD:1318263 6480464 exemestane results in increased expression of MYBL2 mRNA CTD PMID:17254854 fenvalerate increases expression EXP 6480464 fenvalerate results in increased expression of MYBL2 mRNA CTD PMID:30307764 fipronil decreases expression EXP 6480464 fipronil results in decreased expression of MYBL2 mRNA CTD PMID:23962444 folic acid multiple interactions ISO RGD:1318264 6480464 Folic Acid inhibits the reaction [1, 2-Dimethylhydrazine results in increased expression of MYBL2 mRNA] CTD PMID:22206623 furan increases expression EXP 6480464 furan results in increased expression of MYBL2 mRNA CTD PMID:25539665 furan decreases expression EXP 6480464 furan results in decreased expression of MYBL2 mRNA CTD PMID:27387713 genistein increases expression ISO RGD:1318263 6480464 Genistein results in increased expression of MYBL2 mRNA CTD PMID:16474171 gentamycin decreases expression EXP 6480464 Gentamicins results in decreased expression of MYBL2 mRNA CTD PMID:22061828 geraniol decreases expression ISO RGD:1318263 6480464 geraniol results in decreased expression of MYBL2 mRNA CTD PMID:27683099 glycidol increases expression EXP 6480464 glycidol results in increased expression of MYBL2 mRNA CTD PMID:24915197 glycidol decreases expression EXP 6480464 glycidol results in decreased expression of MYBL2 mRNA CTD PMID:24395379 Heliotrine increases expression EXP 6480464 heliotrine results in increased expression of MYBL2 mRNA CTD PMID:32419051 hydralazine multiple interactions ISO RGD:1318263 6480464 [Hydralazine co-treated with Valproic Acid] results in increased expression of MYBL2 mRNA CTD PMID:17183730 hydrogen peroxide decreases expression ISO RGD:1318263 6480464 Hydrogen Peroxide results in decreased expression of MYBL2 mRNA CTD PMID:12419474 indometacin multiple interactions ISO RGD:1318263 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of MYBL2 mRNA CTD PMID:28628672 L-ascorbic acid multiple interactions ISO RGD:1318263 6480464 [Quercetin co-treated with Ascorbic Acid] results in increased expression of MYBL2 mRNA CTD PMID:17639512 Lasiocarpine increases expression EXP 6480464 lasiocarpine results in increased expression of MYBL2 mRNA CTD PMID:32419051 Lasiocarpine increases expression ISO RGD:1318263 6480464 lasiocarpine results in increased expression of MYBL2 mRNA CTD PMID:32234424 lipopolysaccharide increases expression ISO RGD:1318264 6480464 Lipopolysaccharides results in increased expression of MYBL2 mRNA CTD PMID:12057914 lucanthone decreases expression ISO RGD:1318263 6480464 Lucanthone results in decreased expression of MYBL2 mRNA CTD PMID:21148553 methotrexate increases expression EXP 6480464 Methotrexate results in increased expression of MYBL2 mRNA CTD PMID:16005536 methylseleninic acid decreases expression ISO RGD:1318263 6480464 methylselenic acid results in decreased expression of MYBL2 mRNA CTD PMID:12517777 N-methyl-4-phenylpyridinium decreases expression ISO RGD:1318263 6480464 1-Methyl-4-phenylpyridinium results in decreased expression of MYBL2 mRNA CTD PMID:24810058 naphthalene increases expression ISO RGD:1318264 6480464 naphthalene results in increased expression of MYBL2 mRNA CTD PMID:18978301 nickel dichloride affects expression EXP 6480464 nickel chloride affects the expression of MYBL2 mRNA CTD PMID:22546817 nicotine decreases expression ISO RGD:1318263 6480464 Nicotine results in decreased expression of MYBL2 mRNA CTD PMID:16949557 oxaliplatin multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of MYBL2 mRNA CTD PMID:25729387 oxaliplatin decreases expression EXP 6480464 oxaliplatin results in decreased expression of MYBL2 mRNA CTD PMID:25729387 paracetamol affects expression ISO RGD:1318264 6480464 Acetaminophen affects the expression of MYBL2 mRNA CTD PMID:17562736 paracetamol decreases expression ISO RGD:1318264 6480464 Acetaminophen results in decreased expression of MYBL2 mRNA CTD PMID:17942131 phenethyl isothiocyanate decreases expression ISO RGD:1318263 6480464 phenethyl isothiocyanate results in decreased expression of MYBL2 mRNA CTD PMID:26678675 phenobarbital decreases expression ISO RGD:1318264 6480464 Phenobarbital results in decreased expression of MYBL2 mRNA CTD PMID:25270620 phenobarbital affects expression ISO RGD:1318263 6480464 Phenobarbital affects the expression of MYBL2 mRNA CTD PMID:19159669 phytoestrogen increases expression ISO RGD:1318263 6480464 Phytoestrogens results in increased expression of MYBL2 mRNA CTD PMID:18310284 pirinixic acid decreases expression ISO RGD:1318264 6480464 pirinixic acid results in decreased expression of MYBL2 mRNA CTD PMID:25270620 progesterone decreases expression ISO RGD:1318264 6480464 Progesterone results in decreased expression of MYBL2 mRNA CTD PMID:16966611 quercetin multiple interactions ISO RGD:1318263 6480464 [Quercetin co-treated with Ascorbic Acid] results in increased expression of MYBL2 mRNA CTD PMID:17639512 resveratrol multiple interactions ISO RGD:1318263 6480464 [Coumestrol co-treated with resveratrol] results in increased expression of MYBL2 mRNA CTD PMID:19167446 resveratrol increases expression ISO RGD:1318263 6480464 resveratrol results in increased expression of MYBL2 mRNA CTD PMID:19167446 senecionine increases expression EXP 6480464 senecionine results in increased expression of MYBL2 mRNA CTD PMID:32419051 silicon dioxide increases expression ISO RGD:1318264 6480464 Silicon Dioxide results in increased expression of MYBL2 mRNA CTD PMID:29341224 sirolimus multiple interactions ISO RGD:1318264 6480464 [TGFB1 protein co-treated with Sirolimus] results in decreased expression of MYBL2 protein CTD PMID:12417722 sodium arsenite increases expression ISO RGD:1318263 6480464 sodium arsenite results in increased expression of MYBL2 mRNA CTD PMID:12016162 , PMID:29301061 sodium dichromate affects expression EXP 6480464 sodium bichromate affects the expression of MYBL2 mRNA CTD PMID:22110744 sodium dichromate decreases expression ISO RGD:1318264 6480464 sodium bichromate results in decreased expression of MYBL2 mRNA CTD PMID:31558096 sulforaphane multiple interactions EXP 6480464 [sulforafan co-treated with Aflatoxin B1] affects the expression of MYBL2 mRNA CTD PMID:25450479 sunitinib decreases expression ISO RGD:1318263 6480464 Sunitinib results in decreased expression of MYBL2 mRNA CTD PMID:31533062 tamoxifen affects expression ISO RGD:1318264 6480464 Tamoxifen affects the expression of MYBL2 mRNA CTD PMID:17555576 Tanshinone I increases expression ISO RGD:1318263 6480464 tanshinone results in increased expression of MYBL2 mRNA CTD PMID:15849732 testosterone decreases expression ISO RGD:1318263 6480464 Testosterone results in decreased expression of MYBL2 mRNA CTD PMID:21592394 testosterone multiple interactions ISO RGD:1318263 6480464 [Testosterone co-treated with Calcitriol] results in decreased expression of MYBL2 mRNA CTD PMID:21592394 thioacetamide increases expression EXP 6480464 Thioacetamide results in increased expression of MYBL2 mRNA CTD PMID:23411599 tioguanine increases expression EXP 6480464 Thioguanine results in increased expression of MYBL2 mRNA CTD PMID:16005536 titanium dioxide increases expression EXP 6480464 titanium dioxide results in increased expression of MYBL2 mRNA CTD PMID:30012374 topotecan decreases expression EXP 6480464 Topotecan results in decreased expression of MYBL2 mRNA CTD PMID:25729387 topotecan multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of MYBL2 mRNA CTD PMID:25729387 Tributyltin oxide decreases expression ISO RGD:1318264 6480464 bis(tri-n-butyltin)oxide results in decreased expression of MYBL2 mRNA CTD PMID:17942131 , PMID:25270620 triclosan decreases expression ISO RGD:1318263 6480464 Triclosan results in decreased expression of MYBL2 mRNA CTD PMID:30510588 trimellitic anhydride increases expression ISO RGD:1318264 6480464 trimellitic anhydride results in increased expression of MYBL2 mRNA CTD PMID:19042947 troglitazone decreases expression ISO RGD:1318263 6480464 troglitazone results in decreased expression of MYBL2 mRNA CTD PMID:11834241 valproic acid increases methylation ISO RGD:1318263 6480464 Valproic Acid results in increased methylation of MYBL2 gene CTD PMID:29154799 valproic acid decreases expression ISO RGD:1318263 6480464 Valproic Acid results in decreased expression of MYBL2 mRNA CTD PMID:28001369 valproic acid multiple interactions ISO RGD:1318263 6480464 [Hydralazine co-treated with Valproic Acid] results in increased expression of MYBL2 mRNA CTD PMID:17183730 vorinostat decreases expression ISO RGD:1318263 6480464 vorinostat results in decreased expression of MYBL2 protein CTD PMID:10597302 zaragozic acid A increases expression EXP 6480464 squalestatin 1 results in increased expression of MYBL2 mRNA CTD PMID:27225895 zaragozic acid A decreases expression ISO RGD:1318264 6480464 squalestatin 1 results in decreased expression of MYBL2 mRNA CTD PMID:27225895
Gene-Chemical Interaction Annotations
